Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Circulation

• Publication date

  2005-07-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.104.528166PMID 15983242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial ( ALLHAT )

  2006cited by this paper
• Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial

  2004cited by this paper
• Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme

  2004cited by this paper
• 1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM

  2004cited by this paper
• Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity

  2004cited by this paper
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int

  2004cited by this paper
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination, in high risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• 835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM)

  2004cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

  2003cited by this paper
• Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.

  2003cited by this paper
• Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

  2003cited by this paper
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

  2003cited by this paper
• Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  2002cited by this paper
• Angiotensin blockade prevents type 2 diabetes by formation of fat cells.

  2002cited by this paper
• Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension

  2002cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol☆

  2002cited by this paper
• Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

  2001cited by this paper
• Ramipril and the development of diabetes.

  2001cited by this paper
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  1999cited by this paper
• Fatty acids, lipotoxicity and insulin secretion

  1999cited by this paper
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

  1998cited by this paper

• Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.

  2025influential citation
• Comparative analysis of hemodialysis and peritoneal dialysis on the risk of new onset diabetes mellitus.

  2024cites this paper
• Cardio‐renal‐metabolic disease in primary care setting

  2023cites this paper
• Metabolic Approaches for the Treatment of Dilated Cardiomyopathy

  2023cites this paper
• Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States

  2023cites this paper
• Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials

  2022cites this paper
• Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence

  2022cites this paper
• Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.

  2022cites this paper
• The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms

  2021cites this paper
• Diabetes and treatment of chronic heart failure in a large real‐world heart failure population

  2021cites this paper
• Relationship Between Diabetes Mellitus and the Prognosis of Ischemic Heart Failure

  2021cites this paper
• Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.

  2021cites this paper
• Treating heart failure in patients with diabetes: the view of the cardiologist.

  2021cites this paper
• Renin Angiotensin Aldosterone System, Glucose Homeostasis, and Prevention of Type 2 Diabetes: Mechanistic Insights and Evidence from Major Clinical Trials

  2021cites this paper
• Fighting HFpEF in women

  2021cites this paper
• Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPARγ

  2020cites this paper
• Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy

  2020influential citation
• Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy

  2020cites this paper
• Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

  2020cites this paper
• Heart Failure in Type 2 Diabetes Mellitus.

  2019cites this paper
• Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis.

  2019cites this paper
• Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?

  2019cites this paper
• Metabolic effects of cardiovascular drugs.

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.

  2019cites this paper
• [Gerontology Issues in Cardiology Practice].

  2019cites this paper
• Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature

  2019cites this paper
• Hypertension Treatment in Diabetes: Focus on Heart Failure Prevention.

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.

  2019cites this paper
• Evidence-Based Management of the Patient with Congestive Heart Failure

  2018cites this paper
• Interactions between coronary artery endothelial cells and leukocyte MPs shed in response to E. coli lipopolysaccharide : in-vitro and ex-vivo studies of the impact of vascular ageing and of high glucose

  2018cites this paper
• Double trouble: managing diabetic emergencies in patients with heart failure

  2018cites this paper
• A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition

  2017cites this paper
• Evaluation of Epicardial Adipose Tissue in Patients of Type 2 Diabetes Mellitus by Echocardiography and its Correlation with Intimal Medial Thickness of Carotid Artery

  2017cites this paper
• Novel insight into the dangerous connection between diabetes and heart failure

  2016cites this paper
• Pathogenesis of Macrovascular Complications in Diabetes

  2016cites this paper
• Metabolic effects of an AT 1-receptor blockade combined with HCTZ in cardiac risk patients : a non interventional study in primary care

  2015influential citation
• Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders

  2015cites this paper
• Der Einfluss von Angiotensinrezeptor Blockade mit Irbesartan auf die Insulinsensitivität bei Patienten mit systolischer Herzinsuffizienz - Ergebnisse einer randomisierten, Placebo kontrollierten

  2015cites this paper
• Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.

  2015cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?

  2015cites this paper
• Impact of Left Ventricular Assist Device on Diabetes Management: An Evaluation through Case Analysis and Clinical Impact

  2014cites this paper
• Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry.

  2014cites this paper
• Candesartan Cilexetil 32 mg/Hydrochlorothiazide 25 mg in Unselected Patients with High or Very High Cardiovascular Risk: Efficacy, Safety, and Metabolic Impact

  2014cites this paper
• Diabetes-related heart failure.

  2014cites this paper
• Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies

  2014cites this paper
• [Effects of liver hydrolysate on the blood glucose in metabolic syndrome model rats (SHR/NDmcr-cp)].

  2013cites this paper
• The role of angiotensin II in nonalcoholic steatohepatitis.

  2013cites this paper
• PPAR and Local Renin-Angiotensin Systems in Cardiovascular and Metabolic Diseases Associated with Obesity: A Unifying Hypothesis

  2013cites this paper
• Improvement in Glycemic Control After Left Ventricular Assist Device Implantation in Advanced Heart Failure Patients With Diabetes Mellitus

  2013cites this paper
• メタボリックシンドロームモデルラット (SHR/NDmcr-cp) における肝臓水解物の血糖に及ぼす影響

  2013cites this paper
• Antihypertensive treatment in diabetic patients. Review of current data.

  2013cites this paper
• Cardiogenic diabetes

  2013cites this paper
• Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles

  2013cites this paper
• Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk.

  2013cites this paper
• Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension

  2012cites this paper
• Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.

  2012cites this paper
• Congestive Heart Failure and Diabetes: Balancing Glycemic Control with Heart Failure Improvement

  2012cites this paper
• Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.

  2012cites this paper
• Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis.

  2012cites this paper
• Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement.

  2012cites this paper
• The Endothelium, Cardiovascular Disease, and Therapy

  2012cites this paper
• A Retrospective Longitudinal Cohort Study of Antihypertensive Drug Use and New-Onset Diabetes in Taiwanese Patients

  2012cites this paper
• Candesartan in the treatment of arterial hypertension and its cardiovascular complications

  2012cites this paper
• Relationship between Telmisartan Dose and Glycaemic Control in Japanese Patients with Type 2 Diabetes Mellitus and Hypertension

  2012cites this paper
• Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)

  2012cites this paper
• High E/e′ disrupts the rapid lowering of blood glucose in response to exercise training

  2012cites this paper
• Candesartan Cilexetil/Hydrochlorothiazide Treatment in High-Risk Patients with Type 2 Diabetes Mellitus and Microalbuminuria

  2012cites this paper
• ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus

  2012cites this paper
• Choice of antihypertensive treatment in subjects with pre-diabetes. Is there a dream after the navigator.

  2011cites this paper
• Hydrochlorothiazide Compared to Candesartan Treatment Increases Adipose Tissue Gene Expression and Circulating Levels of Serum Amyloid A in Hypertensive Patients

  2011cites this paper
• Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.

  2011cites this paper
• Should the Metabolic Syndrome Patient with Prediabetes Be Offered Pharmacotherapy?

  2011cites this paper
• Candesartan cilexetil: an update

  2011cites this paper
• Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.

  2011cites this paper
• An overview of candesartan in clinical practice

  2011cites this paper
• Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension

  2011cites this paper
• Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients

  2011cites this paper
• Cardiac Resynchronization Therapy Reduces the Risk of Cardiac Events in Patients With Diabetes Enrolled in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT)

  2011cites this paper
• The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes

  2010cites this paper
• The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats.

  2010cites this paper
• Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse

  2010cites this paper
• Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome.

  2010cites this paper
• The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus

  2010cites this paper
• Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers.

  2010cites this paper
• Progression of cardiovascular damage: the role of renin-angiotensin system blockade.

  2010cites this paper
• Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice

  2010cites this paper
• Effects of Low Doses of Captopril or Losartan in Improving Glycemic Control by Oral Hypoglycemic Agents in Type 2 DM Patients

  2010cites this paper
• Risk factors and outcomes associated with posttransplant diabetes mellitus in kidney transplant recipients.

  2010cites this paper
• Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?

  2010cites this paper
• Effect of valsartan on the incidence of diabetes and cardiovascular events.

  2010cites this paper
• Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

  2010influential citation
• Metabolismo energético del corazón y sus proyecciones en el tratamiento de la insuficiencia cardíaca

  2010cites this paper
• Direct renin inhibition ameliorates cardiovascular complications and pancreatic injury in obese and type 2 diabetic mice

  2010cites this paper
• Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.

  2010cites this paper
• Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial

  2010cites this paper
• [Heart energy metabolism and its role in the treatment of heart failure].

  2010cites this paper
• RGS2 determines the preventive effects of ARBs against vascular remodeling: toward personalized medicine of anti-hypertensive therapy with ARBs

  2010cites this paper
• Glycemia and prognosis of patients with chronic heart failure--subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial.

  2010cites this paper
• High prevalence of abnormal glucose metabolism in young adult patients with complex congenital heart disease.

  2009cites this paper
• Aging-associated insulin resistance predisposes to hypertension and its reversal by exercise: the role of vascular vasorelaxation to insulin

  2009cites this paper